OSU-T315, CAS 2070015-22-2

Product Description: OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain)[1]. OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner[2]. OSU-T315 causes cell death through apoptosis and autophagy[1].

Applications: Cancer-Kinase/protease

Formula: C30H30F3N5O

References: [1]Su-Lin Lee,et al Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor.J Med Chem. 2011 Sep 22; 54(18): 6364–6374/[2]Liu TM, et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8;125(2):284-95.

CAS Number: 2070015-22-2

Molecular Weight: 533.59

Compound Purity: 99.88

Research Area: Cancer

Solubility: DMSO : ≥ 260 mg/mL

Target: Apoptosis;Autophagy;Integrin

• SKU: MEXHY-18676-10.1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-18676-10.1
• Package Unit: 10 mM/1 ml
• Quantity Unit: STK